NO20061906L - Terapeutisk middel for mesoteliom - Google Patents

Terapeutisk middel for mesoteliom

Info

Publication number: NO20061906L
Authority: NO; Norway
Prior art keywords: mesothelioma; therapeutic agent; antagonist; antibody; interleukin
Prior art date: 2003-10-17

Application number

NO20061906A

Other languages

English (en)

Norwegian (no)

Inventor

Tadamitsu Kishimoto

Norihiro Nishimotot

Yasuo Adachi

Koichi Takayama

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-17

Filing date

2006-04-28

Publication date

2006-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34463281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061906(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-28 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2006-06-21 Publication of NO20061906L publication Critical patent/NO20061906L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Mobile Radio Communication Systems (AREA)

NO20061906A 2003-10-17 2006-04-28 Terapeutisk middel for mesoteliom NO20061906L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003358152		2003-10-17
PCT/JP2004/015674 WO2005037315A1 (fr)	2003-10-17	2004-10-15	Agent de traitement de mesotheliome

Publications (1)

Publication Number	Publication Date
NO20061906L true NO20061906L (no)	2006-06-21

Family

ID=34463281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20061906A NO20061906L (no)	2003-10-17	2006-04-28	Terapeutisk middel for mesoteliom

Country Status (23)

Country	Link
US (2)	US20070134242A1 (fr)
EP (1)	EP1690550B1 (fr)
JP (1)	JP4651541B2 (fr)
KR (1)	KR101193708B1 (fr)
CN (1)	CN1874790B (fr)
AR (1)	AR046290A1 (fr)
AU (1)	AU2004281139B2 (fr)
BR (1)	BRPI0415505A (fr)
CA (1)	CA2542691C (fr)
DK (1)	DK1690550T3 (fr)
ES (1)	ES2392824T3 (fr)
HK (1)	HK1096588A1 (fr)
IL (1)	IL174909A (fr)
MX (1)	MXPA06003768A (fr)
MY (1)	MY149856A (fr)
NO (1)	NO20061906L (fr)
NZ (1)	NZ546557A (fr)
PL (1)	PL1690550T3 (fr)
RU (2)	RU2554942C2 (fr)
SI (1)	SI1690550T1 (fr)
TW (1)	TWI350175B (fr)
WO (1)	WO2005037315A1 (fr)
ZA (1)	ZA200602973B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2322216A1 (fr)	1997-03-21	2011-05-18	Chugai Seiyaku Kabushiki Kaisha	Agent thérapeutique ou préventif pour les maladies liées aux lymphocytes T sensibilisés comprenant l'antagoniste IL-6 en tant qu'ingrédient actif
UA80091C2 (en)	2001-04-02	2007-08-27	Chugai Pharmaceutical Co Ltd	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2003211991B2 (en)	2002-02-14	2008-08-21	Chugai Seiyaku Kabushiki Kaisha	Antibody-containing solution formulations
GB2401040A (en)	2003-04-28	2004-11-03	Chugai Pharmaceutical Co Ltd	Method for treating interleukin-6 related diseases
WO2005090405A1 (fr)	2004-03-24	2005-09-29	Chugai Seiyaku Kabushiki Kaisha	Sous-type d'anticorps humanisé contre un récepteur de l'interleukine-6
RU2446826C2 (ru)	2005-10-14	2012-04-10	Фукуока Юниверсити	Агенты для подавления повреждения трансплантированных островков после трансплантации островков
EP1941908B1 (fr) *	2005-10-21	2015-08-19	Chugai Seiyaku Kabushiki Kaisha	Agent therapeutique pour maladie de coeur
AR057582A1 (es) *	2005-11-15	2007-12-05	Nat Hospital Organization	Agentes para suprimir la induccion de linfocitos t citotoxicos
AR059213A1 (es) *	2006-01-27	2008-03-19	Univ Keio	Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
CN101479381B (zh)	2006-03-31	2015-04-29	中外制药株式会社	调控抗体血液动力学的方法
JP5754875B2 (ja)	2006-04-07	2015-07-29	国立大学法人大阪大学	筋再生促進剤
BRPI0806812B8 (pt)	2007-01-23	2021-09-14	Chugai Pharmaceutical Co Ltd	Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
US8178101B2 (en)	2007-05-21	2012-05-15	Alderbio Holdings Inc.	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
KR20160005134A (ko) *	2007-05-21	2016-01-13	앨더바이오 홀딩스 엘엘씨	신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US9701747B2 (en)	2007-05-21	2017-07-11	Alderbio Holdings Llc	Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en)	2007-05-21	2011-11-22	Alderbio Holdings Llc	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en)	2007-05-21	2012-08-28	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
EP3187506B1 (fr)	2007-05-21	2019-03-27	AlderBio Holdings LLC	Anticorps anti-il-6 et leur utilisation
US7906117B2 (en) *	2007-05-21	2011-03-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) *	2007-05-21	2009-09-24	Kovacevich Brian R	Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) *	2007-05-21	2013-03-26	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
CN106519025B (zh)	2007-09-26	2021-04-23	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
ES2566957T3 (es)	2007-09-26	2016-04-18	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
PE20091174A1 (es) *	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
NZ602884A (en)	2008-04-11	2014-08-29	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TW201503898A (zh) *	2008-06-05	2015-02-01	Chugai Pharmaceutical Co Ltd	神經浸潤抑制劑
US8658612B2 (en) *	2008-07-30	2014-02-25	National University Corporation Okayama University	Therapeutic agent for malignant mesothelioma and immunostimulant
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
MX364874B (es) *	2008-11-25	2019-05-09	Alderbio Holdings Llc	Anticuerpos de il-6 y uso de los mismos.
US8337847B2 (en)	2008-11-25	2012-12-25	Alderbio Holdings Llc	Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en)	2008-11-25	2013-04-16	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
US9212223B2 (en)	2008-11-25	2015-12-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en)	2008-11-25	2015-03-31	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en)	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
TW201600110A (zh) *	2009-07-31	2016-01-01	Shin Maeda	癌之轉移抑制劑
CN102596995B (zh)	2009-10-26	2015-08-12	弗·哈夫曼-拉罗切有限公司	用于生产糖基化免疫球蛋白的方法
US9468676B2 (en)	2009-11-24	2016-10-18	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US9775921B2 (en)	2009-11-24	2017-10-03	Alderbio Holdings Llc	Subcutaneously administrable composition containing anti-IL-6 antibody
TWI505838B (zh)	2010-01-20	2015-11-01	Chugai Pharmaceutical Co Ltd	Stabilized antibody solution containing
HUE060454T2 (hu) *	2010-05-28	2023-03-28	Chugai Pharmaceutical Co Ltd	Daganatellenes T-sejt-választ fokozó szer
CN103180461A (zh) *	2010-07-25	2013-06-26	纽约大学	用于间皮瘤预后的组合物和方法
KR102116202B1 (ko)	2010-11-08	2020-05-28	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
EP2643018B1 (fr)	2010-11-23	2020-10-14	AlderBio Holdings LLC	Anticorps anti-il-6 utilisés pour le traitement de la stomatite
RU2642318C2 (ru)	2010-11-30	2018-01-24	Чугаи Сейяку Кабусики Кайся	Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
MX342810B (es) *	2011-03-03	2016-10-13	Apexigen Inc	Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
DK3011974T3 (en)	2011-06-02	2018-11-12	Univ Louisville Res Found Inc	Anti-nucleolin agent-conjugated nanoparticles
MX339762B (es)	2011-09-28	2016-05-27	Univ Autonoma Del Estado De Morelos	Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
JO3370B1 (ar)	2011-11-10	2019-03-13	Regeneron Pharma	طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2014088040A1 (fr)	2012-12-06	2014-06-12	国立大学法人金沢大学	Procédé de traitement du mésothéliome
US10782290B2 (en)	2013-06-11	2020-09-22	National Center Of Neurology And Psychiatry	Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
WO2015000865A1 (fr)	2013-07-04	2015-01-08	F. Hoffmann-La Roche Ag	Dosage immunologique à interférence supprimé et pour détecter des anticorps anti-médicament dans des échantillons de sérum
US10774148B2 (en)	2015-02-27	2020-09-15	Chugai Seiyaku Kabushiki Kaisha	Composition for treating IL-6-related diseases
EP3291839A1 (fr)	2015-05-05	2018-03-14	The University of Louisville Research Foundation, Inc.	Nanoparticules conjuguées à un agent antinucléoline en tant que radiosensibiliseurs et agents de contraste d'imagerie par résonance magnétique (irm) et/ou en rayons x
ES2888801T3 (es)	2015-05-19	2022-01-07	Nat Center Neurology & Psychiatry	Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM)
US11484591B2 (en)	2016-02-22	2022-11-01	Ohio State Innovation Foundation	Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US11033496B2 (en)	2017-03-17	2021-06-15	The Regents Of The University Of Michigan	Nanoparticles for delivery of chemopreventive agents
WO2018203545A1 (fr)	2017-05-02	2018-11-08	国立研究開発法人国立精神・神経医療研究センター	Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
WO2019078344A1 (fr)	2017-10-20	2019-04-25	学校法人兵庫医科大学	Composition médicinale contenant un anticorps du recepteur anti-il -6 pour prévenir l'adhérence post-chirurgicale
EP3947737A2 (fr)	2019-04-02	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US521628A (en)		1894-06-19		Housekeeping-cabinet
US5670373A (en)	1988-01-22	1997-09-23	Kishimoto; Tadamitsu	Antibody to human interleukin-6 receptor
JP2914672B2 (ja)	1989-01-17	1999-07-05	中外製薬株式会社	Ｂｓｆ▲下２▼アンタゴニスト
ATE144713T1 (de) *	1989-07-20	1996-11-15	Tadamitsu Kishimoto	Antikörper gegen menschlichen interleukin-6- rezeptor
JP2898040B2 (ja)	1990-01-26	1999-05-31	忠三岸本	ｇｐ１３０蛋白質に対する抗体
US5210075A (en)	1990-02-16	1993-05-11	Tanabe Seiyaku Co., Ltd.	Interleukin 6 antagonist peptides
ES2134212T3 (es)	1991-04-25	1999-10-01	Chugai Pharmaceutical Co Ltd	Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
FR2694767B1 (fr)	1992-08-13	1994-10-21	Innotherapie Lab Sa	Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en)	1993-07-21	1999-03-30	Chugai Seiyaku Kabushiki Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en)	1993-10-06	1995-05-01	Board Of Regents, The University Of Texas System	A monoclonal anti-human il-6 receptor antibody
JPH07324097A (ja)	1994-05-30	1995-12-12	Daicel Chem Ind Ltd	インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
EP2319535A3 (fr)	1994-10-21	2011-08-31	Chugai Seiyaku Kabushiki Kaisha	Composition pharmaceutique de traitement de maladies provoquées par la production d'IL-6
IT1274350B (it)	1994-12-06	1997-07-17	Angeletti P Ist Richerche Bio	Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it)	1994-12-14	1997-07-24	Angeletti P Ist Richerche Bio	Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
JPH08245414A (ja) *	1995-01-27	1996-09-24	Private Biolog Corp	Ｉｌ−６関連疾患の治療用組成物および方法
FR2733250B1 (fr)	1995-04-21	1997-07-04	Diaclone	Anticorps monoclonaux anti-gp130, et leurs utilisations
JPH08311098A (ja)	1995-05-22	1996-11-26	Daicel Chem Ind Ltd	新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US5571513A (en)	1995-05-31	1996-11-05	The Board Of Regents Of The University Of Oklahoma	Anti-gp130 monoclonal antibodies
AU6038196A (en) *	1995-06-07	1996-12-30	Private Biologicals Corporation	Compositions and methods of treating il-6 associated disease s
US20020187150A1 (en)	1997-08-15	2002-12-12	Chugai Seiyaku Kabushiki Kaisha	Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CN100374159C (zh)	1998-03-17	2008-03-12	中外制药株式会社	一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
JP2004500810A (ja) *	1999-12-09	2004-01-15	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体
JP4776145B2 (ja)	2000-10-25	2011-09-21	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する乾癬の予防又は治療剤
WO2002036165A1 (fr)	2000-10-27	2002-05-10	Chugai Seiyaku Kabushiki Kaisha	Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
UA80091C2 (en)	2001-04-02	2007-08-27	Chugai Pharmaceutical Co Ltd	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2004204261A1 (en) *	2003-01-15	2004-07-29	Solbec Pharmaceuticals Limited	Method of modulating IL-6
US20050090453A1 (en) *	2003-01-15	2005-04-28	Solbec Pharmaceuticals Co., Ltd.	Methods of modulating IL-6
US20040161426A1 (en) *	2003-02-04	2004-08-19	Mohit Trikha	Use of IL-6 antagonists in combination with steroids to enhance apoptosis
GB2401040A (en)	2003-04-28	2004-11-03	Chugai Pharmaceutical Co Ltd	Method for treating interleukin-6 related diseases
US20060094645A1 (en) *	2004-10-06	2006-05-04	Oliver Lawless	Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists

2004
- 2004-10-15 CA CA2542691A patent/CA2542691C/fr not_active Expired - Fee Related
- 2004-10-15 NZ NZ546557A patent/NZ546557A/en not_active IP Right Cessation
- 2004-10-15 SI SI200431946T patent/SI1690550T1/sl unknown
- 2004-10-15 RU RU2010102911/15A patent/RU2554942C2/ru not_active IP Right Cessation
- 2004-10-15 MY MYPI20044273A patent/MY149856A/en unknown
- 2004-10-15 PL PL04792816T patent/PL1690550T3/pl unknown
- 2004-10-15 BR BRPI0415505-0A patent/BRPI0415505A/pt not_active IP Right Cessation
- 2004-10-15 KR KR1020067007246A patent/KR101193708B1/ko not_active IP Right Cessation
- 2004-10-15 JP JP2005514876A patent/JP4651541B2/ja not_active Expired - Lifetime
- 2004-10-15 WO PCT/JP2004/015674 patent/WO2005037315A1/fr active Application Filing
- 2004-10-15 US US10/575,455 patent/US20070134242A1/en not_active Abandoned
- 2004-10-15 TW TW093131346A patent/TWI350175B/zh not_active IP Right Cessation
- 2004-10-15 ES ES04792816T patent/ES2392824T3/es not_active Expired - Lifetime
- 2004-10-15 AR ARP040103743A patent/AR046290A1/es unknown
- 2004-10-15 MX MXPA06003768A patent/MXPA06003768A/es active IP Right Grant
- 2004-10-15 EP EP04792816A patent/EP1690550B1/fr not_active Expired - Lifetime
- 2004-10-15 DK DK04792816.3T patent/DK1690550T3/da active
- 2004-10-15 RU RU2006116896/15A patent/RU2392967C2/ru not_active IP Right Cessation
- 2004-10-15 AU AU2004281139A patent/AU2004281139B2/en not_active Ceased
- 2004-10-15 CN CN200480031888XA patent/CN1874790B/zh not_active Expired - Fee Related
2006
- 2006-04-10 IL IL174909A patent/IL174909A/en not_active IP Right Cessation
- 2006-04-12 ZA ZA200602973A patent/ZA200602973B/en unknown
- 2006-04-28 NO NO20061906A patent/NO20061906L/no not_active Application Discontinuation
2007
- 2007-02-09 HK HK07101545.1A patent/HK1096588A1/xx not_active IP Right Cessation
2008
- 2008-04-10 US US12/081,126 patent/US8802092B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2542691A1 (fr)	2005-04-28
JPWO2005037315A1 (ja)	2006-12-28
MY149856A (en)	2013-10-31
KR20070029632A (ko)	2007-03-14
TW200517126A (en)	2005-06-01
JP4651541B2 (ja)	2011-03-16
KR101193708B1 (ko)	2012-10-22
US20080274106A1 (en)	2008-11-06
ZA200602973B (en)	2007-07-25
MXPA06003768A (es)	2006-06-23
RU2010102911A (ru)	2011-08-10
HK1096588A1 (en)	2007-06-08
WO2005037315A1 (fr)	2005-04-28
AR046290A1 (es)	2005-11-30
EP1690550B1 (fr)	2012-08-08
RU2554942C2 (ru)	2015-07-10
RU2006116896A (ru)	2007-12-10
US8802092B2 (en)	2014-08-12
DK1690550T3 (da)	2012-11-05
BRPI0415505A (pt)	2006-12-12
CA2542691C (fr)	2013-09-24
IL174909A0 (en)	2006-08-20
ES2392824T3 (es)	2012-12-14
AU2004281139A1 (en)	2005-04-28
US20070134242A1 (en)	2007-06-14
CN1874790A (zh)	2006-12-06
NZ546557A (en)	2010-01-29
RU2392967C2 (ru)	2010-06-27
AU2004281139B2 (en)	2011-01-20
TWI350175B (en)	2011-10-11
IL174909A (en)	2010-11-30
CN1874790B (zh)	2011-11-16
EP1690550A4 (fr)	2009-07-15
EP1690550A1 (fr)	2006-08-16
SI1690550T1 (sl)	2012-12-31
PL1690550T3 (pl)	2013-01-31

Publication	Publication Date	Title
NO20061906L (no)	2006-06-21	Terapeutisk middel for mesoteliom
TW200507849A (en)	2005-03-01	Methods for treating interleukin-6 related diseases
NO20091734L (no)	2009-06-04	Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
NO20070785L (no)	2007-04-02	Sammensetninger for levering av svaert vannloselige medikamenter.
NO20064127L (no)	2006-12-13	Terapeutisk middel for Auris interna forstyrrelse, inneholdende IL-6 antagonist som aktiv bestanddel
NO20062649L (no)	2006-09-01	Biarylsulfonamider og metoder for anvendelse av disse
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20061737L (no)	2006-05-31	Aminosubstituerte erylamino B2 adrenergiske receptoragonister
NO20056132L (no)	2006-01-26	Krystallinsk form av beta2 adrenergisk receptoragonist
NO20060001L (no)	2006-03-02	Nye P2X7-reseptorantagonister og deres anvendelse
EA201000491A1 (ru)	2010-08-30	Аминометилзамещенные тетрациклиновые соединения
DK1320531T3 (da)	2011-01-03	Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
NO20030374L (no)	2003-01-24	Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
ATE469897T1 (de)	2010-06-15	Indazolcarbonsäureamidverbindungen
DK1456212T3 (da)	2007-04-02	6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
MY133625A (en)	2007-11-30	Peptide deformylase inhibitors
MXPA05013758A (es)	2006-03-13	Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
ATE547400T1 (de)	2012-03-15	N-alkylierte diaminopropanderivate als modulatoren der chemokinrezeptoraktivität
DK1511764T3 (da)	2012-12-03	Peptider og peptidomimetika, som er egnede til hæmning af aktiviteten af prostaglandin f2alfa-receptor
MXPA05012705A (es)	2006-02-08	Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
SE0300445D0 (sv)	2003-02-18	New combination
AU2003223634A1 (en)	2004-11-26	Peptide deformylase inhibitors
DK1420789T3 (da)	2007-09-17	Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
AU2003304490A1 (en)	2005-04-21	Peptide deformylase inhibitors
NO20044917L (no)	2005-01-27	Fremgangsmate og mellomprodukter for fremstilling av ikke-nukleoside HIV-reverstranskriptase-inhibitorer

Legal Events

Date	Code	Title	Description
2014-05-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application